What's New?

Everything you need to
know when you're on
the go

What if we could
reduce the cost
of HIV treatment

making it possible to treat
more patients, for less?

What if first-line
treatment could
reduce the risk
of resistance?

and the need to resort to
more expensive second-
and third- line treatment?

previous arrow
next arrow
Considerations for the Introduction of TLD in National Programs: PEPFAR Guidance on Developing Clinical and Programmatic Recommendations

ICAP has developed the following document that aims to supports country program managers to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination tablet of tenofovir, lamivudine and dolutegravir (TLD). It combines summaries of current normative guidance, available evidence, and programmatic considerations to inform the practical decisions that countries will need to make to develop comprehensive guidance on the use of TLD.


"The information provided on this website is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government."